Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13161928 | 0.94 | HCRTR1 (0.42) | OPRM1SIGMAR1KMT2AMEN1HCRTR1 | |
| SCHEMBL17767856 | 0.86 | SIGMAR1 (0.51) | OPRM1SIGMAR1KMT2AKCNH2 | |
| SCHEMBL29967808 | 0.82 | SIGMAR1 (0.54) | SIGMAR1KMT2AMEN1GAAL3MBTL1 | |
| SCHEMBL27143931 | 0.81 | MEN1 (0.46) | OPRM1KMT2AMEN1GSK3AGSK3B | |
| SCHEMBL6132736 | 0.81 | GAA (0.44) | OPRM1SIGMAR1GSK3AGSK3BELANE | |
| Hydrochloric Acid SCHEMBL28272548 | 0.81 | SIGMAR1 (0.53) | SIGMAR1KMT2AMEN1GAAL3MBTL1 | |
| SCHEMBL22394905 | 0.77 | HCRTR1 (0.50) | OPRM1KMT2AMEN1HCRTR1HCRTR2 | |
| SCHEMBL2074739 | 0.77 | ALDH1A1 (0.42) | KMT2AMEN1ELANECTSGGAA | |
| SCHEMBL15571839 | 0.77 | ALDH1A1 (0.45) | OPRM1SIGMAR1KCNH2ELANECTSG | |
| SCHEMBL2075062 | 0.77 | ALDH1A1 (0.45) | OPRM1SIGMAR1KCNH2ELANECTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924278-B2 | Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | TAC3, TACR1, SSTR5 | OPRM1 306/4885SIGMAR1 1572/4885KMT2A 829/4885 |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | TACR1, NPSR1, SSTR2 | OPRM1 222/4885SIGMAR1 670/4885KMT2A 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.